Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415656 | 1.00 | SIGMAR1 (0.53) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL8871048 | 1.00 | SIGMAR1 (0.53) | SIGMAR1OPRD1AVPR1A | |
| Methane SCHEMBL6919510 | 0.98 | SIGMAR1 (0.51) | SIGMAR1OPRD1AVPR1A | |
| Hydrochloric Acid SCHEMBL78480 | 0.98 | SIGMAR1 (0.51) | SIGMAR1OPRD1AVPR1A | |
| Hydrochloric Acid SCHEMBL29717167 | 0.98 | SIGMAR1 (0.51) | SIGMAR1OPRD1AVPR1A | |
| Ethane SCHEMBL8577252 | 0.96 | SIGMAR1 (0.54) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL2330750 | 0.93 | SIGMAR1 (0.48) | SIGMAR1OPRD1AVPR1A | |
| Propane SCHEMBL8890366 | 0.93 | SIGMAR1 (0.51) | SIGMAR1AVPR1A | |
| Butane SCHEMBL8604221 | 0.92 | SIGMAR1 (0.50) | SIGMAR1AVPR1A | |
| SCHEMBL31059145 | 0.89 | HTR2A (0.49) | SIGMAR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | claimed |
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | claimed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1716142-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | Sanofi-Aventis (FR) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080357-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | WO | claimed |
| EP-4747251-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2025019479-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025010314-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12162887-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-4260623-A | Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof | WARNER-LAMBERT COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0002283-A1 | Substituted 1,3-dihydrospiro (benzo(c)thiophenes), process for their preparation and these compounds for use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-13 | — | — | EP | disclosed |
| US-4031224-A | 1,3-Dihydro-heteroarylspiro (isobenzofuran)s | AMERICAN HOECHST CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4024263-A | ANALGESIC, ANTICONVULSANT, ANTIDEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4024263-A | ANALGESIC, ANTICONVULSANT, ANTIDEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4024263-A | ANALGESIC, ANTICONVULSANT, ANTIDEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3985889-A | 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962259-A | TRANQUILIZERS, ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | SIGMAR1 4755/4885OPRD1 4765/4885AVPR1A 3453/4885 |
| US-12162887-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885OPRD1 6/4885AVPR1A 1/4885 |
| US-20250066378-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885OPRD1 6/4885AVPR1A 1/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | SIGMAR1 4454/4885OPRD1 4564/4885AVPR1A 3588/4885 |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | SIGMAR1 161/4885OPRD1 194/4885AVPR1A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.